BREAKING NEWS: Wall Street Journal article puts spotlight on the potential of new anticoagulants taking fresh aim at one of cardiology’s toughest challenges.

Anthos Therapeutics is led by a world-class executive team highly experienced in the successful development, approval, and commercialization of products across a wide range of therapeutic areas.

Bill Meury is the CEO and a member of the Board of Directors of Anthos Therapeutics. Meury joins after successfully leading KarunaTherapeutics, and brings significant expertise in strategic planning, commercialization, business development and licensing, R&D partnerships and new product launches. Read more here.


Dan Bloomfield, M.D

Chief Medical Officer

Erika Dahl, Ph.D.

Program Manager

Mike Doremus

Head of Technical Operations

Debra Freedholm

SVP, Clinical Operations

Jonathan Freeman, Ph.D

Co-Founder and Chief Operating Officer

Gi Gi Galiano

Vice President Program & Risk Management and Human Resources Operations

Alyssa Goldstein

Senior Administrative & Operations Coordinator

Bruce Hug, M.D., Ph.D

Vice President, Clinical Development

Alisha Lundholm, CPA, MSA

Corporate Controller

David McIntyre B.EC., LL.B., CPA, MBA

Chief Financial Officer

Nik Mehta, Ph.D

Chief Technical and Regulatory Officer

Bill Meury


Jessica Patrick Seabrook

Office Operations & Events Manager

Janeen Salter

Director of Clinical Operations

Drew Young

Chief Commercial Officer and Head of Patient Experience


Connie Cullen, PH.D

Principal Consultant

Yasser Khder, M.D, PH.D

Founder & Senior Consultant at MYRA Life Science Services


Scott Beardsley

Ari Brettman, M.D

Raymond Camahort

Nicholas Galakatos, Ph.D

Bill Meury


Greg Norden

Paris Panayiotopoulos

Richard Pasternak, M.D

Peter Renehan, M.D.

Vasilisa (Vaska) Sazonov, Ph.D.